Microfluidics Market Report 2026

The microfluidics market size has grown rapidly in recent years. It will grow from $10.33 billion in 2025 to $11.89 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to growth in laboratory-on-a-chip research, increasing demand for miniaturized diagnostic devices, adoption in pharmaceutical R&D, expansion of analytical and clinical testing, development of silicon and glass-based microfluidic devices.

The microfluidics market size is expected to see rapid growth in the next few years. It will grow to $20.73 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to rising adoption in point-of-care diagnostics, growth in personalized medicine applications, expansion of polymer-based microfluidics, increasing integration with IoT and smart lab systems, advancements in high-throughput screening technologies. Major trends in the forecast period include integration of microfluidics in drug delivery systems, adoption of microfluidics in clinical diagnostics, expansion of pharmaceutical and life science research applications, development of industrial and environmental microfluidics solutions, advancement in high-precision fluid manipulation technologies.

The rise in clinical studies for cell-based therapies has significantly contributed to the growth of the microfluidics market during the historical period. Microfluidics has emerged as a promising platform for advancing biomanufacturing in drug, gene, and cell therapies by enabling enhanced synthesis of nanoscale drug and gene delivery systems, microencapsulation of drugs or cells, intracellular delivery of macromolecules, and the fabrication of macroscale constructs from micro-nano fibers. For example, in July 2023, the American Society of Gene and Cell Therapy, a US-based medical and scientific development organization, reported a 58% increase in non-oncology gene and cell therapy clinical trials in the second quarter of 2023 compared to the first quarter. Thus, the growing number of clinical studies focused on cell-based therapies is expected to drive the growth of the microfluidics market during the forecast period.

Major companies operating in the microfluidics market are concentrating on developing sophisticated solutions, such as lab-on-a-chip devices and integrated microfluidic platforms, to improve diagnostic accuracy, shorten sample processing time, and enhance point-of-care testing capabilities. Lab-on-a-chip devices are miniaturized systems that consolidate multiple laboratory functions onto a single chip, allowing faster and more precise analyses with minimal sample volumes. For example, in March 2024, Takara Bio, a Japan-based scientific reagents manufacturer, introduced the first commercial dissolvable microfluidic lentiviral transduction enhancer. This product employs a unique dissolvable microfluidic platform that enables precise regulation of the transduction process, improving the delivery of lentiviral vectors into target cells. The enhancer is designed to substantially boost the efficiency of lentiviral transduction, which is vital for gene therapy applications, ensuring more effective gene delivery into cells. Additionally, the microfluidic system streamlines the experimental setup, making it user-friendly for researchers without requiring extensive technical expertise.

In January 2025, bioMérieux SA, a France-based global leader in in vitro diagnostics, finalized the acquisition of SpinChip Diagnostics ASA for an enterprise value of approximately 0.15 USD billion (EUR 138 million). With this acquisition, bioMérieux seeks to strengthen its microfluidics-enabled point-of-care diagnostic capabilities by incorporating SpinChip’s advanced microfluidic immunoassay technology, which provides rapid, high-sensitivity results from small blood samples and broadens the company’s diagnostic portfolio. SpinChip Diagnostics ASA is a Norway-based diagnostics firm that develops next-generation microfluidic testing solutions for both acute and chronic disease diagnosis.

Major companies operating in the microfluidics market report are Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Fluidigm Corporation, Dolomite Microfluidics, PerkinElmer, Inc., Sphere Fluidics Limited, Micronit Micro Technologies B.V., Fluigent, Elveflow, Cellix Ltd., Microliquid S.L., Biosurfit S.A., FlowJEM, uFluidix, QuantWave Technologies Inc., Harvard Bioscience, Inc., Abaxis, Inc., OPKO Health, Inc., Abbott, Stämm.

North America was the largest region in the microfluidics market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the microfluidics market are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microfluidics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The microfluidics market includes revenues earned by entities by developing molecular sensors based on bioassays, such as DNA amplification and analysis, cell separation, and immunoassay, among many more examples. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.